Neuropathies may be detected even earlier, in subjects with prediabetes. [12] [13] [14] Indeed, polyneuropathy and CAN have been reported in 11% to 25% 12, 13 and 5.9% to 11.4% 11 of patients with prediabetes, respectively. In such patients, it is principally peak postprandial glucose excursions that are implicated in polyneuropathy. 15 , 16 Bongaerts et al 16 provided evidence of a J-shaped relationship between polyneuropathy and quartiles of 2-hour postload glucose challenge but not with fasting glucose. Németh et al 17 have also shown that 120 minutes postprandial glucose was an important independent determinant of sensory nerve dysfunction in subjects with impaired glucose tolerance. The prevalence of both polyneuropathy 16 and CAN 11 in prediabetes has been found highest in patients with a combination of impaired fasting glucose and impaired glucose tolerance. Importantly, the ADA has very recently accepted the presence of neuropathy in the setting of prediabetes (mainly impaired glucose tolerance) and has suggested polyneuropathy screening in those patients with prediabetes who have symptoms. 1 This is important, given the association of both somatic and autonomic neuropathy with cardiovascular disease (CVD). 18 Indeed, peripheral neuropathy was reported to increase the risk of CVD events (stroke, transient ischemic attack, nonfatal myocardial infarction, coronary revascularization, and congestive heart failure) by 33% (hazard ratio [HR]: 1.33, 95% confidence interval [CI]: 1.02-1.75; P ¼ .04) among patients with T2DM, free of CVD, after adjustment for standard CVD risk factors. 19 It has also recently been shown that peripheral neuropathy is a harbinger of asymptomatic myocardial ischemia in patients with T2DM with a negative medical history of CVD. 20, 21 Furthermore, with respect to CAN, prolonged corrected QT interval was associated with a 2-to 3-fold increased risk in mortality. 22 Other abnormal indices, namely R-R intervals during deep breathing have also been associated with poor survival among patients with diabetes (T1DM and T2DM), mainly due to sudden cardiac death or macrovascular disease. 23 Furthermore, during a follow-up of 3.5 years among 8135 patients with T2DM at high CVD risk in the Action to Control Cardiovascular Risk in Diabetes trial, a more than double all-cause mortality (HR: 2.14, CI: 1.37-3.37; P ¼ .009) and CVD mortality (HR: 2.62, CI: 1.40-4.91; P ¼ .003) were reported among patients with CAN compared with those without. 24 New data indicate that Charcot osteoarthropathy (a specific diabetic manifestation related mainly to peripheral neuropathy and secondarily to autonomic neuropathy), which was traditionally regarded as a diabetic complication in patients without peripheral arterial disease, may be associated with increased mortality rate, possibly attributed to coronary artery disease.
Granted the aforementioned associations, diagnostic workup for diabetic neuropathy should start early and patients exhibiting this complication merit meticulous care. As reported by the ADA in 2017, the assessment of peripheral neuropathy should include temperature and pinprick sensation (for small-fiber function), as well as 128-Hz tuning fork and 10-g Semmes-Weinstein monofilament testing (for large-fiber function).
1 However, we should not fail to notice that the latter detects only more advanced peripheral neuropathy. 26 Fortunately, in the most recent years, a growing research interest has led to the evaluation of various valuable diagnostic tools. 27 Among them, Neuropad ® (TrigoCare International, Wiehl, Drabenderhöhe, Germany) (a novel indicator test for sudomotor dysfunction) has proven its utility, particularly in the exclusion of polyneuropathy both in an elderly population (aged 61-82 years) with prediabetes (sensitivity 57.8% and negative predictive value 76.5%) 14 and among newly diagnosed (within the first year of diagnosis) patients with T1DM and T2DM (sensitivity of 87.5% and 65.1% and negative predictive value of 95.4% and 64.3%, respectively). 7 This diagnostic performance of Neuropad renders it an excellent screening tool in prediabetes, in the same way as it has been shown in a large study of patients with T2DM. 28 More recently, corneal confocal microscopy, a noninvasive technique for the in vivo study of the human cornea with a high sensitivity (82%) and a moderate specificity (52%) for the diagnosis of peripheral neuropathy, 29 has also proven its utility for the detection of small nerve fiber pathology in recently (during the past 12 months) diagnosed patients with T2DM aged 18 to 69 years. 8 Further studies have also provided evidence for the use of this modality in subjects with impaired glucose tolerance to detect small-fiber dysfunction. 30, 31 Corneal confocal microscopy has proven its utility in the diagnosis of autonomic neuropathy in patients with diabetes (T1DM and T2DM), yielding a very high sensitivity (up to 100%) and a moderate specificity (up to 78%). 32 This is very interesting, especially in the context of the recent attempts to simplify the diagnosis of CAN against the gold standard but time-demanding, Ewing's battery. Indeed, Stranieri et al 33 have reported that the heart rate variation test during deep breathing is the best single test for CAN diagnosis. In addition, we have shown a high diagnostic utility of a single cardiovascular reflex test, the 30:15 ratio, mainly to exclude CAN (sensitivity 96% and negative predictive value 94%). 34 In conclusion, neuropathy should no longer be considered a late complication of diabetes. In contrast, it may start very early and could occur even before the diagnosis of diabetes. Talking of love, the poet W. B. Yeats observed that "one cannot begin it too soon" 35 : the very same can also be said of neuropathy in patients with T1DM or T2DM. This needs to be kept in mind, especially given the availability of diagnostic tools for the early detection of CAN and peripheral neuropathy, [36] [37] [38] both of which may carry a worse prognosis.
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